Drug Study (Mucosulvan, Verorab, Tetanus Toxoid)

"Tetanus Toxoid"

GENERIC NAME: Anti-tetanus serum
BRAND NAME: Tetanus Toxoid
GENERAL CLASSIFICATION: EPI vaccine, Anti-tetanus

INDICATION:
 Tetanus Toxoid is indicated for booster injection only for persons 7 yrs of age and older against tetanus.
 Primary immunization schedule for children under 7 yrs of age should consist of five doses of vaccine containing tetanus toxoid.
 Tetanus Toxoid is not to be used for treatment of tetanus infection.
 As with any vaccine, vaccination with tetanus toxoid may not protect 100% of susceptible individuals.
DOSAGES:
 After the initial immunization series is completed, a booster dose of 0.5mL of tetanus toxoid should be given intramuscularly every 10 yrs to maintain adequate immunity.
SIDE EFFECT/ ADVERSE REACTION: o Body System as a whole:
Redness, warmth, edema, induration with or without tenderness as well as urticaria, and rash. Malaise, transient fever, pain, hypotension, nausea, and arthralgia
NURSING CONSIDERATION:
 Shake well the vial before withdrawing each dose
 Special care should be taken to ensure that the injection does not enter the blood vessel
 For Nursing Mothers: Tetanus Toxoid does not affect the safety of mothers who are breastfeeding or their infants. Breastfeeding does not adversely affect immune response and is not a contraindication for vaccination
 For Pediatric Use:
Safety and effectiveness of tetanus toxoid in infants below the age of 6 weeks has not been established. However, this vaccine is not indicated for children under 7 yrs of age.
 For Geriatric Use:
Tetanus Toxoid should only be used in geriatric patients known to have received a primary series of tetanus-containing vaccine, since many such as persons have no prior immunity.

"Verorab"

GENERIC NAME: Rabies vaccine
BRAND NAME: Verorab
GENERAL CLASSIFICATION: Anti-rabies vaccine
INDICATION:
 All subjects at a permanent risk should be vaccinated
 A serological test is recommended every 6 months
 A booster injection should be administered if the antibody titer is below the level considered to guarantee protection: 0.5iu/mL
DOSAGES:
 Primary Vaccination: 3 injections on days 0, 7 and 28. Booster injection 1 year later then every 5 years.
 Vaccination for non-immunized subjects: The dosage is the same for adults and children. Includes five 0.5mL injections on days 0, 3, 7, 14 and 28.
SIDE EFFECT/ ADVERSE REACTION:
 Minor local reactions such as pain, erythema, edema, pruritus, induration at the injection site
 Systemic reactions such as fever, shivering, faintness, asthenia, headaches, dizziness, nausea, abdominal pains, rash
NURSING CONSIDERATION:
 Use with caution on patients with a known allergy to neomycin
 Do not inject by the intravascular route
 Immunoglobulins and rabies vaccine must not be associated in the same syringe or injected at the same site
 For immunodeficient subjects, this may be conducted 2-4 weeks following the vaccination

"Mucosolvan"

GENERIC NAME: Ambroxol Hydrochloride
BRAND NAME: Mucosolvan and Mucoangin
GENERAL CLASSIFICATION: Expectorant
INDICATION:
 Secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.

DOSAGES:
 Adults: daily dose of 30 mg (one Ambroxol tablet )to 120 mg (4 Ambroxol tablets) taken in 2 to 3 divided doses
 Children up to 2 years: half a teaspoonful Ambroxol syrup twice daily
 Children 2 - 5 years: half a teaspoonful Ambroxol syrup 3 times daily
 Children over 5 years: One teaspoonful Ambroxol syrup 2-3 times daily.
SIDE EFFECT/ ADVERSE REACTION:
 Occasional gastrointestinal side effects may occur but these are normally mild.
NURSING CONSIDERATION:
 Inform the doctor If the patient is suffering from a febrile illness, an acute